a) Why waste any significant resources on MNKD as Afrezza is not approved (has had 2 crl's), and another inhaled insulin product has already failed.

b) Afrezza is still a long way from any potential approval date - there may be a superior candidate for treating diabetes that comes along before any potential Afrezza approval that would make Afrezza, at best, a short term success.

c) MNKD has significant capital requirements, let's wait and squeeze them as much as possible.

d) Al Mannis impossible to deal with and just wants too much $$'s for us to partner with him.

e) We aren't interested.

f) Surgical intervention will be the treatment of choice for type 2 diabetics in the future:

http://www.nytimes.com/2012/03/27/science/to-combat-diabetes-weight-loss-surgery-works-better-than-medicine-studies-find.html?pagewanted=all